Edwin Klumper joins Cristal Therapeutics as Chief Medical Officer

He will be responsible for the clinical strategy and development of Cristal Therapeutics’ nanomedicines

Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec platform, has hired Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines.

Before joining the firm, Klumper served as interim CEO of Dutch SMS-oncology, which he co-founded in 2007. He acted as CMO since the inception of the company until 2013.

Prior to SMS-oncology, he worked at Nabi Biopharmaceuticals as Vice-President Marketing & Sales Europe, at Amgen as Business Unit Director for the Netherlands, for the UK and as Brand Director Europe, at ASTA Medica as Product Manager, and at start-up Yew Tree Pharmaceuticals as Medical Director.

You may also like

Research & Development

Cristal Therapeutics and PX Biosolutions to develop vaccines using CriVac nanotechnology

Platform enables the tailormade development of well-characterised polymeric nanoparticles of a specific size
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Subscribe now